Familial breast cancer
- PMID: 22356477
- DOI: 10.1111/j.1399-0004.2012.01859.x
Familial breast cancer
Abstract
Since the localization and discovery of the first high-risk breast cancer (BC) genes in 1990, there has been a substantial progress in unravelling its familial component. Increasing numbers of women at risk of BC are coming forward requesting advice on their risk and what they can do about it. Three groups of genetic predisposition alleles have so far been identified with high-risk genes conferring 40-85% lifetime risk including BRCA1, BRCA2 and TP53. Moderate risk genes (20-40% risk) including PALB1, BRIP, ATM and CHEK2, and a host of low-risk common alleles identified largely through genome-wide association studies. Currently, only BRCA1, BRCA2 and TP53 are used in clinical practice on a wide scale, although testing of up to 50-100 gene loci may be possible in the future utilizing next-generation technology.
© 2012 John Wiley & Sons A/S.
Similar articles
-
Breast cancer genes: beyond BRCA1 and BRCA2.Front Biosci (Landmark Ed). 2013 Jun 1;18(4):1358-72. doi: 10.2741/4185. Front Biosci (Landmark Ed). 2013. PMID: 23747889 Review.
-
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.JAMA. 2006 Mar 22;295(12):1379-88. doi: 10.1001/jama.295.12.1379. JAMA. 2006. PMID: 16551709
-
Gene analysis techniques and susceptibility gene discovery in non-BRCA1/BRCA2 familial breast cancer.Surg Oncol. 2015 Jun;24(2):100-9. doi: 10.1016/j.suronc.2015.04.003. Epub 2015 Apr 13. Surg Oncol. 2015. PMID: 25936246 Review.
-
BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives.Eur J Cancer. 2006 May;42(8):1143-50. doi: 10.1016/j.ejca.2005.11.032. Epub 2006 Apr 27. Eur J Cancer. 2006. PMID: 16644204
-
Hereditary breast cancer; Genetic penetrance and current status with BRCA.J Cell Physiol. 2019 May;234(5):5741-5750. doi: 10.1002/jcp.27464. Epub 2018 Dec 14. J Cell Physiol. 2019. PMID: 30552672 Review.
Cited by
-
The European BRCA patent oppositions and appeals: coloring inside the lines.Nat Biotechnol. 2013 Aug;31(8):704-10. doi: 10.1038/nbt.2644. Nat Biotechnol. 2013. PMID: 23929344 No abstract available.
-
Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas.Nat Genet. 2014 Feb;46(2):182-7. doi: 10.1038/ng.2855. Epub 2013 Dec 22. Nat Genet. 2014. PMID: 24362817 Free PMC article.
-
Population-based study of recurrent DNA damage response gene variants in breast cancer cases.Breast Cancer Res Treat. 2025 May;211(1):195-202. doi: 10.1007/s10549-025-07634-5. Epub 2025 Feb 26. Breast Cancer Res Treat. 2025. PMID: 40009290 Free PMC article.
-
Germline TP53 mutational spectrum in French Canadians with breast cancer.BMC Med Genet. 2015 Apr 12;16:24. doi: 10.1186/s12881-015-0169-y. BMC Med Genet. 2015. PMID: 25925845 Free PMC article.
-
Hereditary breast cancer: the era of new susceptibility genes.Biomed Res Int. 2013;2013:747318. doi: 10.1155/2013/747318. Epub 2013 Mar 21. Biomed Res Int. 2013. PMID: 23586058 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous